121 related articles for article (PubMed ID: 2291871)
21. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.
Edstein MD; Shanks GD; Teja-Isavadharm P; Rieckmann KH; Webster HK
Br J Clin Pharmacol; 1994 Jan; 37(1):67-70. PubMed ID: 8148220
[TBL] [Abstract][Full Text] [Related]
22. High-performance liquid chromatography of proguanil, cycloguanil and 4-chlorophenylbiguanide using hydrophobic pairing ion and its application to serum assay.
Moody RR; Selkirk AB; Taylor RB
J Chromatogr; 1980 Jun; 182(3-4):359-67. PubMed ID: 7391178
[TBL] [Abstract][Full Text] [Related]
23. Analysis of proguanil and its metabolites by application of the sweeping technique in micellar electrokinetic chromatography.
Taylor RB; Reid RG; Low AS
J Chromatogr A; 2001 May; 916(1-2):201-6. PubMed ID: 11382292
[TBL] [Abstract][Full Text] [Related]
24. Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone.
Edstein MD; Veenendaal JR; Rieckmann KH
Chemotherapy; 1990; 36(3):169-76. PubMed ID: 2186899
[TBL] [Abstract][Full Text] [Related]
25. Determination of proguanil and metabolites in small sample volumes of whole blood stored on filter paper by high-performance liquid chromatography.
Kolawole JA; Taylor RB; Moody RR
J Chromatogr B Biomed Appl; 1995 Dec; 674(1):149-54. PubMed ID: 8749264
[TBL] [Abstract][Full Text] [Related]
26. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.
Ward SA; Helsby NA; Skjelbo E; Brøsen K; Gram LF; Breckenridge AM
Br J Clin Pharmacol; 1991 Jun; 31(6):689-92. PubMed ID: 1867963
[TBL] [Abstract][Full Text] [Related]
27. Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound.
Helsby NA; Ward SA; Parslew RA; Friedmann PS; Rhodes LE
Acta Derm Venereol; 1998 Mar; 78(2):81-3. PubMed ID: 9534880
[TBL] [Abstract][Full Text] [Related]
28. OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil.
Matthaei J; Seitz T; Jensen O; Tann A; Prukop T; Tadjerpisheh S; Brockmöller J; Tzvetkov MV
Clin Pharmacol Ther; 2019 Jan; 105(1):190-200. PubMed ID: 29882324
[TBL] [Abstract][Full Text] [Related]
29. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
[TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.
McGready R; Stepniewska K; Edstein MD; Cho T; Gilveray G; Looareesuwan S; White NJ; Nosten F
Eur J Clin Pharmacol; 2003 Oct; 59(7):545-52. PubMed ID: 12955371
[TBL] [Abstract][Full Text] [Related]
31. Excretion of proguanil in human saliva.
Onyeji CO; Ogunbona FA; Dixon PA
J Pharm Pharmacol; 1989 Dec; 41(12):872-3. PubMed ID: 2576454
[TBL] [Abstract][Full Text] [Related]
32. Improved method for the simultaneous determination of proguanil and its metabolites by high-performance liquid chromatography and solid-phase extraction of 100-microl capillary blood samples dried on sampling paper.
Bergqvist Y; Funding L; Kaneko A; Krysén B; Leek T
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):141-9. PubMed ID: 9869374
[TBL] [Abstract][Full Text] [Related]
33. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz.
Soyinka JO; Onyeji CO
Eur J Pharm Sci; 2010 Feb; 39(4):213-8. PubMed ID: 19961932
[TBL] [Abstract][Full Text] [Related]
34. The pharmacokinetics of proguanil in human subjects following a single oral dose.
Chiluba EM; Fletcher KA; Price AH
Afr J Med Med Sci; 1987 Mar; 16(1):43-6. PubMed ID: 3037875
[TBL] [Abstract][Full Text] [Related]
35. Effects of cimetidine on the pharmacokinetics of proguanil in healthy subjects and in peptic ulcer patients.
Kolawole JA; Mustapha A; Abdul-Aguye I; Ochekpe N; Taylor RB
J Pharm Biomed Anal; 1999 Sep; 20(5):737-43. PubMed ID: 10701981
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status.
Kusaka M; Setiabudy R; Chiba K; Ishizaki T
Am J Trop Med Hyg; 1996 Feb; 54(2):189-96. PubMed ID: 8619446
[TBL] [Abstract][Full Text] [Related]
37. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
38. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans.
Funck-Brentano C; Bosco O; Jacqz-Aigrain E; Keundjian A; Jaillon P
Clin Pharmacol Ther; 1992 May; 51(5):507-12. PubMed ID: 1587064
[TBL] [Abstract][Full Text] [Related]
39. Superior antimalarial activity of proguanil to cycloguanil after in vitro bioconversion.
Ramanaiah TV; Gajanana A
Trans R Soc Trop Med Hyg; 1988; 82(3):358-9. PubMed ID: 3068842
[No Abstract] [Full Text] [Related]
40. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
